RT Journal Article
SR Electronic
T1 Radiomic Feature Spatially Characterizes the Transition of Normal Lung Parenchyma to Small Airways Disease in COPD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.26.23290532
DO 10.1101/2023.05.26.23290532
A1 Bell, Alexander J.
A1 Ram, Sundaresh
A1 Labaki, Wassim W.
A1 Hoff, Benjamin A.
A1 Wang, Jennifer M.
A1 Murray, Susan
A1 Kazerooni, Ella A.
A1 Galban, Stefanie
A1 Lynch, David A.
A1 Humphries, Stephen M.
A1 Martinez, Fernando J.
A1 Hatt, Charles R.
A1 Han, MeiLan K.
A1 Galban, Craig J.
YR 2023
UL http://medrxiv.org/content/early/2023/06/05/2023.05.26.23290532.abstract
AB Purpose Small airways disease (SAD), a major cause of airflow obstruction in COPD patients, has been identified as a precursor to emphysema. Nevertheless, there is a lack of clinical techniques that can quantify the progression of SAD. We aim to determine if our Parametric Response Mapping (PRM) method to quantify SAD offers insight into lung progression from healthy to emphysema.Materials and Methods PRM metrics quantifying normal lung (PRMNorm) and functional SAD (PRMfSAD) were generated from CT scans collected as part of the COPDGene study (n=8956). Volume density (V) and Euler-Poincaré Characteristic (χ) maps, measures of extent and coalescence of pocket formations, respectively, were determined for both PRMNorm and PRMfSAD. Association with COPD severity, emphysema, and spirometric measures were assessed via multivariable regression models.Results Across all GOLD, we observed a strong linear correlation between χfSAD and χNorm (ρ =-0.745, p<0.001). Values of χfSAD and χNorm were found to flip signs in unison between GOLD 2 and 4, demonstrating an inversion in parenchymal topology. For subjects with COPD, multivariable analysis showed that both χfSAD (β of 0.106, p<0.001) and VfSAD (β of 0.065, p=0.004) were independently associated with FEV1% predicted. V and χ measures for PRMfSAD and PRMNorm were independently associated with the amount of emphysema.Conclusions We demonstrated that χ of fSAD and Norm have independent value when associated with lung function and emphysema, even when considering the amount of each (i.e., VfSAD, VNorm). Our approach for quantifying pocket formations of PRMfSAD from normal lung parenchyma (PRMNorm) may show promise as a CT readout of emphysema onset.Competing Interest StatementW.W.L. reports personal fees from Konica Minolta and Continuing Education Alliance. B.A.H. and C.J.G. are co-inventors and patent holders of tPRM, which the University of Michigan has licensed to Imbio, LLC. C.J.G. is co-inventor and patent holder of PRM, which the University of Michigan has licensed to Imbio, LLC. B.A.H. and C.J.G. have financial interest in Imbio, LLC. C.R.H. is employed by Imbio, LLC. D.A.L. reports funds paid to the institution from the NIH, and Boehringer Ingelheim. M.K.H. reports personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Medscape, NACE, MDBriefcase and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. For the remaining authors none were declared. Funding StatementThis work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health Grants R01 HL139690 and R01 HL150023 and by the National Heart, Lung, and Blood Institute of the National Institutes of Health Grants U01 HL089897 and U01 HL089856, which support the COPDGene study. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee comprised of AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer and Sunovion.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study was a secondary analysis of data from COPDGene (ClinicalTrials.gov: NCT00608764). The institutional review boards of all 21 centers participating in the COPDGene study gave ethical approval for the work of that study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets presented in this study are not readily available because they are part of an NIH sponsored clinical trial and require a data use agreement to be signed. For access to COPDGene data visit https://www.copdgene.org/phase-1-study-documents.htm for instructions.